Monthly Archives: December 2018

12 December 2018

Istesso – Parkwalk investment

By |December 12th, 2018|

Parkwalk are delighted to welcome Istesso to its portfolio following an investment from the Parkwalk Opportunities EIS Fund.

Istesso is a drug development company working in the field of immunometabolism. It’s pre-clinical and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune conditions. Istesso’s lead drug, MBS2320, is in a Phase 2a […]

MedaPhor – Parkwalk investment

By |December 11th, 2018|

We are delighted to announce that the Parkwalk Opportunities Fund has  participated in the recent financing round of Medaphor Group plc, the Cardiff University Spin-out and global provider of advanced ultrasound training simulators and ultrasound clinical support for medical professionals.

Parkwalk wins ‘Best Generalist EIS Fund’ in the Investment Week 2018/19 Tax Efficiency Awards

By |December 3rd, 2018|

Parkwalk are delighted to have won ‘Best General EIS Fund’ at Investment Week’s Tax Efficiency Awards 2018 last week, beating last year’s runner’s up prize and matching our win in 2016.

Parkwalk were also highly commended in the ‘Best Exit’ category.

It is always a good validation of our investment strategy to be recognised by industry peers […]

Deal or no deal, should EIS investors be worried about Brexit?

By |December 3rd, 2018|

Given the UK’s Venture Capital Schemes (SEIS, EIS, VCT and SITR) fall under the EU State Aid rules there is the possibility that a ‘hard’ Brexit would allow the Government to loosen restrictions regarding these schemes, but it seems unlikely given the Government’s agenda.

However, under any compromise deal the UK will probably have to […]